46 results about "Allergic asthma" patented technology

Methods for treating or preventing asthma (e.g., allergic asthma, asthma associated with allergic bronchopulmonary aspergillosis (ABPA), moderate-to-severe asthma, persistent asthma or the like) and associated conditions (e.g., ABPA, ABPA comorbid with asthma, ABPA comorbid with cystic fibrosis (CF), ABPA comorbid with asthma and CF) in a subject are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided.

The invention relates to a preparation method and application of an effective part of hyssop officinalis L. The method comprises the following steps: taking hyssop officinalis L., cutting into cun sections, carrying out reflux extraction with ethanol, filtering, merging filtrates, carrying out vacuum concentration, and carrying out vacuum drying to obtain a hyssop officinalis L. ethanol extract; and dissolving the extract in ethanol, extracting with ethyl acetate, concentrating the upper layer under reduced pressure, and drying in vacuum to obtain the effective part of hyssop officinalis. The invention further discloses application of the effective part of the hyssop officinalis obtained through testing in preparation of the anti-allergic asthma medicine.

The invention belongs to the technical field of medicine, and discloses an artemisia annua pollen allergen sublingual drop as well as a preparation process and application thereof.The preparation is realized through the following core processes: firstly, performing raw material screening and supercritical CO2 degreasing pretreatment on artemisia annua pollen at the full-bloom stage in North China, then performing graded ultralow-temperature freezing and crushing, and performing freeze drying to obtain the artemisia annua pollen allergen sublingual drop. The particle size D90 of the superfine powder is smaller than or equal to 4 microns; then adopting a neutral protease and pectinase composite enzymatic hydrolysis system, and combining 4 DEG C low-temperature pulse ultrasound-assisted treatment to accelerate the dissolution of allergens; carrying out tangential flow grading purification and buffer solution replacement by virtue of 100kDa and 5kDa PES (Polyether Sulfonate) ultrafiltration membranes, and introducing a compound stabilizer; and finally, performing three-stage sterile filtration, and performing encapsulation and preservation. According to the process, through multi-link collaborative optimization, the extraction efficiency and activity stability of allergens are improved, and the prepared sublingual drops have the effects of improving allergic rhinitis, allergic asthma and airway inflammation and also have excellent permeability.

The invention discloses an application of glucopyranose galactooligosacharide in preparation of a medicine for treating and / or preventing allergic asthma. The invention finds that the glucopyranose galactooligosaccharide can obviously relieve airway inflammatory reaction of an allergen-induced allergic asthma model, including reducing airway inflammatory factor level, improving airway hyperreactivity and reducing lung inflammatory cell infiltration, and has no abnormal influence on blood routine and main organ functions; the composition has the advantages of small drug application dosage, low pharmaceutical cost, high safety, remarkable drug effect and the like, and has a wide application prospect.

The invention relates to a gene therapy vector nucleic acid construct for allergic diseases and a use method of the gene therapy vector nucleic acid construct. In particular to an expression cassette, the expression cassette comprises the following elements: a promoter, an optional first signal peptide coding sequence, a heavy chain coding sequence of an anti-IgE antibody, an optional linker sequence, an optional second signal peptide coding sequence and a light chain coding sequence of the anti-IgE antibody, and the invention also provides an adeno-associated virus vector containing the expression cassette. The gene expression framework of the adeno-associated virus vector can realize high-level expression of a target gene, and can be used for treating allergic diseases such as allergic asthma and chronic spontaneous urticaria.

The present invention provides an antibody or a conjugated fragment of a citrulline-containing epitope used for the treatment or prevention of diseases associated with the release of extracellular traps from cells, such as neutrophil extracellular trap (NET)-associated pathology (NET-associated pathology) or eosinophil extracellular trap (EET)-associated pathology (EET-associated pathology), and provides a method comprising administering at least one dose of the antibody at a specific concentration. The present invention also provides the method itself. NET-related pathologies include systemic lupus erythematosus (SLE), lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), Sjögren's disease, antiphospholipid syndrome, Behçet's disease, spondylitis, spondyloarthritis, multiple system atrophy, Parkinson's disease, Lewy body dementia, asthma, allergic rhinovirus exacerbated asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulomatous uveitis, granulomatous uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, or wound healing in diabetes, cancer, cancer metastasis, or wound healing in diabetes, cancer, cancer metastasis, and in This includes other NET-related pathologies, such as the health of transplanted organs in vivo or ex vivo.The present invention also relates to wound healing in SLE, lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), Sjögren's disease, antiphospholipid antibody syndrome, Behçet's disease, spondylitis, spondyloarthritis, multiple system atrophy, Parkinson's disease, Lewy body dementia asthma, allergic rhinovirus exacerbating asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulomatous uveitis, granulomatous uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, thrombotic disease, cardiovascular disease, or diabetes, cancer, cancer metastasis, or wound healing in diabetes, cancer, cancer metastasis, and in vivo or ex vivo The present invention provides pharmaceutical compositions and methods for treating and preventing NET-related pathologies, including other NET-related pathologies such as the health of transplanted organs in vivo. NET-related pathologies include eosinophilic diseases or conditions of the skin, respiratory eosinophilic diseases or conditions, gastrointestinal eosinophilic diseases or conditions, allergic diseases or conditions, or eosinophilic diseases or conditions such as helminthic, fungal, viral or bacterial infections.

The invention relates to the technical field of probiotics, in particular to an application of a probiotic (Bifidobacterium longum) in allergic asthma (preventing, relieving or treating allergic asthma). The invention relates to an application of probiotics in allergic asthma, in particular to an application of the probiotics in inhibiting a PI3K / AKT / NF-kappa B signal channel. According to the probiotics disclosed by the invention, activation of a PI3K / AKT / NF-kappa B signal channel is specifically inhibited, immune imbalance is regulated and controlled from the source, and Th2 type immune response is effectively inhibited. Specifically, the total IgE level in serum and the expression of Th2 type cytokines such as IL-4, IL-5 and IL-13 are remarkably reduced, the inflammatory response of the airway mainly caused by eosinophilic granulocyte infiltration is relieved, and the airway high reactivity and airway remodeling are effectively improved. The invention provides a novel intervention strategy which is clear in mechanism, high in safety and capable of treating both symptoms and root causes according to the intestine-lung axis theory, and has a wide application prospect in the aspect of treating allergic asthma.

The present invention provides an antibody comprising citrulline epitope or a binding fragment thereof for use in the treatment or prevention of a disease associated with release of an extracellular trap from a cell, such as a neutrophil extracellular trap (NET)-associated disease (NET-associated disease) or an eosinophil extracellular trap (EET)-associated disease (EET-associated disease), the method comprises administering at least one dose of an antibody at a specific concentration. The present invention also provides these methods themselves. NET related diseases include systemic lupus erythematosus (SLE), lupus, septicemia, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), sicca syndrome, antiphospholipid syndrome, Behcet's disease, spondylitis, spondyloarthropathy, multi-system atrophy, and the like. Parkinson's disease, Lewy body dementia, asthma, allergic rhinovirus aggravated asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulogenic uveitis, granulogenic uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, and the like. Or other NET-related diseases, such as wound healing in diabetic patients, cancer, cancer metastasis, and transplanted organ health in vivo or in vitro. The invention also provides a pharmaceutical composition and a method for treating or preventing NET related diseases. Such as SLE, lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), sicca syndrome, antiphospholipid syndrome, Behcet's disease, spondylitis, spondyloarthropathy, multi-system atrophy, Parkinson's disease, Lewy body dementia, asthma, and the like. Allergic rhinovirus aggravated asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulometric uveitis, granulometric uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, thrombotic disease, cardiovascular disease, and the like. Or other NET-related diseases, such as wound healing in diabetic patients, cancer, cancer metastasis, and transplanted organ health in vivo or in vitro. The EET-related diseases include eosinophilic granulocyte diseases or conditions, such as eosinophilic granulocyte diseases or conditions of skin; a respiratory eosinophilic granulocyte disease or condition; gastrointestinal eosinophilic cell diseases or disorders; allergic diseases or conditions; or worm, fungus, virus or bacterial infection.

The application provides a drug delivery system and a preparation method and application thereof, and relates to the technical field of biomedicine.The drug delivery system comprises mesenchymal stem cell exosomes, black phosphorus quantum dots and budesonide.The drug delivery system contains mesenchymal stem cell exosomes, has the functions of immune regulation, anti-inflammation and lung targeting, realizes lung targeted delivery of the black phosphorus quantum dots loaded with budesonide, and realizes precise regulation of lung temperature by utilizing the near-infrared photothermal effect of the black phosphorus quantum dots in asthma for the first time, so that local hyperthermia for allergic asthma is realized.The drug delivery system utilizes the photothermal effect of the black phosphorus quantum dots in the carrier to control the release speed of budesonide, is beneficial to maintaining the optimal drug concentration in the lung, and is expected to reduce the dosage and frequency of medication and reduce the risk of side effects.The application firstly cooperates the mesenchymal stem cell exosomes, local hyperthermia and the immune regulation effect of budesonide for the treatment of allergic asthma.

The invention discloses application of an inhibitor Acevaltrate targeting PCBP2 in preparation of a medicine for treating allergic asthma, and belongs to the technical field of biological medicine. The invention discloses application of PCBP2 as a molecular target of a drug for treating allergic asthma. The core pathological mechanism of allergic asthma is closely related to M2 polarization of macrophages, and PCBP2 positively drives the polarization process by regulating an STAT6 signal channel. Acevaltrate can specifically inhibit the biological function of PCBP2 and block M2 polarization of macrophages induced by IL-4 / IL-13, so that airway inflammation is relieved, over-generation of IgE (immunoglobulin E) is inhibited, and airway remodeling is improved. The invention further provides a pharmaceutical composition containing the Acevaltrate, a drug combination scheme of the Acevaltrate and an existing asthma treatment drug, and a drug screening system based on a PCBP2-M2 polarization axis. The technology breaks through the limitation of an existing asthma treatment target spot, realizes the trans-boundary application of Acevaltrate from an anti-tumor drug to an anti-asthma drug, provides an accurate and efficient novel treatment strategy for allergic asthma, especially refractory asthma, and has remarkable clinical transformation value and wide application prospects.

The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and / or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.

A method of treating a patient with of one or more of: allergic asthma; chronic rhinosinusitis with nasal polyps; chronic spontaneous urticaria; nasal polyps; food allergy; moderate to severe persistent asthma in patients with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms inadequately controlled with inhaled corticosteroids, the method comprising administering 150 mg / mL omalizumab formulation, wherein the omalizumab is administered subcutaneously by a syringe.

This invention belongs to the field of respiratory disease drugs and fermentation engineering technology, specifically relating to a traditional Chinese medicine composition for improving allergic asthma and its preparation method. The traditional Chinese medicine composition for improving allergic asthma comprises the following components in parts by weight: Ephedra 10-20 parts, Earthworm 1-10 parts, Mulberry Bark 3-17 parts, Poria 6-17 parts, Schisandra Fruit 4-15 parts, Cinnamon Twig 8-18 parts, and Perilla Leaf 1-10 parts. This invention, through screening various high-quality traditional Chinese medicinal materials and rationally combining them, forms a traditional Chinese medicine composition with synergistic effects. This composition is refined through a specific preparation process, effectively preserving the active ingredients in the medicinal materials, and exhibits significant effects in treating and improving allergic asthma. This invention also has advantages such as high safety, few side effects, and suitability for long-term use.

The invention relates to the technical field of medicines, in particular to a pharmaceutical composition and application thereof in preparation of drugs for preventing or treating allergic asthma. The invention relates to a pharmaceutical composition which is definite in active ingredient, high in safety and capable of efficiently treating allergic asthma through a multi-target synergistic effect. The pharmaceutical composition comprises 8-O-debenzoyl paeoniflorin (8-DPF), pentagalloylglucose (PGG), paeoniflorin (PF) and white paeony root crude polysaccharide which serve as active ingredients. According to the composition, through scientific compatibility of the active ingredients of PGG, PF and 8-DPF and the radix paeoniae alba crude polysaccharide, triple effects of anti-inflammation, immunoregulation and bronchial relaxation are achieved, and the problems that an existing medicine is single in target spot, large in side effect, low in bioavailability and the like are solved.

This invention discloses a fusion peptide with synergistic anti-allergic effects, an anti-LTB4 monoclonal antibody, and an anti-allergic drug composition thereof. The fusion peptide is composed of peptide A, which inhibits histamine release, and peptide B, which blocks mast cell activation signals, covalently linked by a linker peptide, which can synergistically inhibit mast cell activation. The anti-LTB4 monoclonal antibody can specifically bind to LTB4, blocking its mediated inflammatory response. Combining the fusion peptide, the anti-LTB4 monoclonal antibody, and myricetin, which has antioxidant activity, forms a multi-target drug composition that can synergistically inhibit allergic reactions from multiple aspects, such as inhibiting mast cell degranulation, blocking the action of inflammatory mediators, and clearing oxidative stress products. In vitro cell experiments and OVA-induced allergic asthma mouse models have demonstrated that the anti-allergic effect of this composition is significantly better than that of a single component, and it has no obvious toxicity, providing a new candidate drug for the efficient treatment of allergic diseases.

The invention relates to the field of immunology and cell therapy, in particular to application of rTh1 cells in preparation of drugs for preventing or treating allergic diseases or inflammatory diseases, the phenotypes of the rTh1 cells are CD3 (+), CD4 (+), CD25 (-), Foxp3 (-), CXCR5 (-), CCR6 (-), CXCR3 (+), CD73 (+) and cMaf (+), and FR4, PD1 and ICOS are highly expressed. The novel T cell subset rTh1 cell has an immunoregulation function, and has an important value in prevention and treatment of allergic diseases such as food allergy and dust mite allergy, atopic dermatitis, allergic asthma, chronic obstructive pulmonary disease and other Th2-type inflammation related skin diseases such as pemphigus bullosa and urticaria.

The invention relates to a B cell immune reset method of a non-integrated in-vivo panCAR based on circRNA, and belongs to the technical field of immunotherapy. The invention provides a B cell resetting preparation. The main component of the B cell resetting preparation is spot type circRNA (Ribonucleic Acid) for coding an anti-CD19 chimeric antigen receptor (Anti-CD19-CAR); firstly, RNA molecules capable of coding Anti-CD19-CAR are subjected to cyclization treatment, then the RNA molecules are loaded on an LNP carrier to form a compound, and the compound can be used for B cell / antibody removal. After the preparation is injected into a body, panCAR cells (including CAR-T, CAR-NK and CAR-Macrophage) can be generated, compared with an antibody therapy and a CAR-T cell therapy, more thorough and safer B cell resetting can be achieved, and the preparation has application potential in the aspects of treating autoimmune diseases and allergic asthma and delaying senescence.

Methods for treating or preventing asthma (e.g., allergic asthma, asthma associated with allergic bronchopulmonary aspergillosis (ABPA), moderate-to-severe asthma, persistent asthma or the like) and associated conditions (e.g., ABPA, ABPA comorbid with asthma, ABPA comorbid with cystic fibrosis (CF), ABPA comorbid with asthma and CF) in a subject are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided.

The invention discloses application of bifidobacterium animalis in relieving respiratory tract allergy symptoms, and belongs to the technical field of microorganisms. The technical problem to be solved is to provide the application of the bifidobacterium animalis in relieving the respiratory tract allergy symptoms, the key point of the technical scheme is the application of the bifidobacterium animalis subsp. Lactis BL-5M in relieving the respiratory tract allergy symptoms, and the preservation number of the bifidobacterium animalis subsp. Lactis BL-5M is CGMCC (China General Microbiological Culture Collection Center) No.33449. The medicine can act on the core mechanism of respiratory tract allergy, and the sneezing / cough frequency caused by respiratory tract stimulation reflex is reduced; the lung tissue enlargement mediated by allergic inflammation is relieved; the ratio of eosinophilic granulocytes in bronchoalveolus is reduced; the concentration of proinflammatory factors IL-4 and IL-5 in bronchoalveolus alveolus is reduced; inflammatory cell infiltration around the lung airway wall is reduced; the IgE content in a body circulation system or local tissues is reduced, meanwhile, the diversity of intestinal flora is improved, anti-inflammatory functional flora is accurately enriched, and the allergic asthma is improved in a targeted manner.

The application provides an animal Bifidobacterium lactis subsp. and an application thereof for preventing and relieving allergic asthma symptoms. The animal Bifidobacterium lactis subsp. is named animal Bifidobacterium lactis subsp. HNU319, has been preserved in the Guangdong Microbial Culture Collection Center (GDMCC) on May 9, 2026, has a preservation number of GDMCC No: 68233, and is classified and named as Bifidobacterium animalis subsp. lactis. The strain exerts an anti-asthma effect through an 'entero-pulmonary axis' regulation network, has the advantages of high safety, clear mechanism and remarkable effect, can be used for developing functional food, microecological preparations or as an active ingredient for the prevention and adjuvant treatment of respiratory diseases, and has a broad industrialization prospect.

Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a thymic stromal lymphopoietin (TSLP) gene. The TSLP RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an TSLP gene. Pharmaceutical compositions that include one or more TSLP RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described TSLP RNAi agents to pulmonary cells, in vivo, provides for inhibition of TSLP gene expression, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including pulmonary inflammation diseases such as asthma, including allergic asthma.

The present invention refers to the medical field. Particularly, the present invention refers to an in vitro method for the diagnosis of allergic asthma or nonallergic asthma in a subject suffering from asthma, or for the differential diagnosis of allergic asthma and nonallergic asthma in a subject suffering from asthma, or for the prognosis of asthma in a subject suffering from asthma, which comprises assessing the expression level of the LGALS3 gene in a biological sample obtained from the subject. It also refers to the in vitro use of the expression level of the LGALS3 gene, or in vitro use of a kit comprising reagents for the same purposes.

The invention belongs to the technical field of medicines, relates to a shikonaceae cynoglossum plant and a new application of an extract of the shikonaceae cynoglossum plant, and in particular relates to an application of the shikonaceae cynoglossum plant and / or the extract of the shikonaceae cynoglossum plant in preparing a medicine for treating allergic diseases. Wherein the allergic diseases comprise various allergic diseases such as allergic rhinitis or syndrome, allergic asthma, allergic tracheitis, allergic skin diseases (eczema, urticaria and dermatitis) and the like. The preparation prepared by taking the shikonaceae cynoglossum plant and the extract thereof as active ingredients has a remarkable curative effect on the allergic diseases, can radically cure the allergic diseases, and is safe and free of side effects. The traditional Chinese medicine belongs to natural medicinal materials and is wide in source, so that a new choice is provided for clinically treating the disease.

Bronchial remodelling is a prominent feature of severe asthma and a potential therapeutic target. Some data indicate that Th17 cytokines in particular IL-22 may be involved in remodelling processes in vitro, and in skin remodelling in vivo. The aim of the inventors was to evaluate if Th17 cytokines are involved in bronchial remodelling in a severe model of allergic asthma, and if this was amplified by co-sensitization with NOD2 agonist, MDP, a ligand favouring Th17 polarization. Dog allergen challenge led to a predominant neutrophilic infiltration in Broncho-alveolar lavage (BAL), increased dog-specific IgE production, airways hyperresponsiveness, and increased Th17 cytokine production. Increased bronchial remodeling was observed in dog allergen challenged mice compared to control. IL-22 deficiency decreased airway hyperresponsiveness, bronchial mucus production as well as peribronchial collagen deposition, in the allergen-challenged group. Th17 cytokines in particular IL-22 participate in the bronchial remodeling in a chronic model of neutrophilic asthma, and may represent a therapeutic target in severe asthma.

The invention discloses application of an NTA10 inhibitor Remodelin in preparation of a medicine for treating allergic asthma, and belongs to the technical field of biological medicine. The core pathological link of the allergic asthma is macrophage M2 polarization imbalance, and NAT10 serving as RNA N4-acetylcytidine modified write enzyme can drive the polarization process. Remodelin is used as an NAT10 specific inhibitor, and can be combined with an NAT10 catalytic structural domain to inhibit the activity of acetyltransferase in a targeted manner, so that an M2 polarization signal channel of macrophages induced by IL-4 / IL-13 is blocked. The invention provides an intraperitoneal injection type medicine taking Remodelin as a core active component, and in-vivo and in-vitro experiments prove that the medicine can remarkably reduce airway inflammatory cell infiltration, down-regulate inflammatory factor release, inhibit high secretion of mucus and airway remodeling, reduce the serum IgE level and effectively improve the pathology phenotype of allergic asthma. According to the invention, the asthma treatment value of the Remodelin-NAT10-macrophage M2 polarization regulation axis is disclosed for the first time, the blank of treating asthma through targeted RNA epigenetic modification is filled, and a brand new treatment scheme is provided for severe asthma.

To provide a novel targeted therapy for the treatment and / or prevention of allergic asthma. [Solution] One particular method includes the step of administering a therapeutic composition comprising an interleukin-33 (IL-33) antagonist, for example, an anti-IL-33 antibody, to a subject in need. Another disclosed method includes the step of administering a therapeutic composition comprising an interleukin-4R (IL-4R) antagonist, for example, an anti-IL-4R antibody, to a subject in need. Yet another disclosed method includes the step of administering a first therapeutic composition comprising an interleukin-33 (IL-33) antagonist, for example, an anti-IL-33 antibody, and a second therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, for example, an anti-IL-4R antibody, to a subject in need.

RNAi agents, compositions comprising RNAi agents, and methods for inhibiting thymic stromal lymphopoietin (TSLP) genes are described. The TSLP RNAi reagents and RNAi reagent conjugates disclosed herein inhibit the expression of the TSLP gene. Also described are pharmaceutical compositions comprising one or more TSLP RNAi agents, optionally in conjunction with one or more additional therapeutic agents. Delivery of the TSLP RNAi agents in vivo to lung cells provides inhibition of TSLP gene expression, which can provide therapeutic benefits to subjects, including human subjects, for the treatment of various diseases, including lung inflammatory diseases such as asthma, including allergic asthma.

This invention relates to the field of pharmaceutical technology, specifically to a pharmaceutical composition for treating allergic asthma, its preparation method, and its application. The pharmaceutical composition for treating allergic asthma of this invention is obtained by combining luteolin, arbutin, and isopyramidal lactone in a specific ratio. The resulting pharmaceutical composition can significantly improve the pathological characteristics of asthma; it can improve pathological changes caused by asthma, such as bronchial stenosis, increased airway mucus, thickening of bronchial smooth muscle, and a large number of inflammatory cells around the airways; it can reduce lung inflammation caused by allergic asthma; it can improve airway remodeling in allergic asthma; it can reduce lung tissue apoptosis and lung damage caused by allergic asthma; it can alleviate the symptoms of allergic asthma and has a protective effect against allergic asthma. It can be used in the preparation of asthma drugs, anti-allergic inflammatory drugs, and drugs that reduce lung tissue apoptosis.

The invention belongs to the field of biomedicine, and relates to an establishment method and application of an allergic asthma susceptible mouse model. According to the method, a filial generation allergic asthma susceptible animal model is constructed through exposure of amoxicillin in a perinatal period, intragastric administration is performed on a female mouse from the 13th day of pregnancy to the 7th day of postpartum in an experiment, and a key window in the perinatal period is covered. And the filial generation is sensitized and excited by ovalbumin (OVA) to establish a standardized asthma model. It is found that exposure of amoxicillin in the perigenic period significantly reduces the richness and diversity of filial generation flora and inhibits taurine metabolism, resulting in significant increase of airway hyperreactivity and eosinophilic granulocytes in alveolar lavage fluid. The cycle of the model is shortened to 28 days, and by combining metabolome and 16S sequencing data, a new mechanism that antibiotics influence asthma susceptibility through a flora-metabolite axis is disclosed, and an experimental basis and a quantitative strategy are provided for clinical intervention.

Provided herein are compounds of Formula I which are thymic stromal lymphopoietin (TSLP) or thymic stromal lymphopoietin receptor (TSLPR) inhibitory compounds, capable of disrupting the protein-protein interaction between TSLP and TSLPR. Compounds of Formula I and compositions thereof modulate activity or inhibit TSLP and TSLPR binding, and are useful for downregulating atopy-relevant pro-inflammatory cytokines. In particular, compounds of Formula I as described herein are useful in the treatment of skin disease, allergic asthma, allergic rhinitis, drug allergies, and food allergies. Furthermore, the compounds described herein are absorbed by the skin. (I)